GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

2026 Jefferies Global Healthcare Conference

Thursday, June 4, 2026

Fireside chat at 12:50 p.m. ET

New York, NY

Goldman Sachs 47^th Annual Global Healthcare Conference

Wednesday, June 10, 2026

Fireside chat at 8:00 a.m. ET

Miami Beach, FL

A webcast of the fireside chats will be available via the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn

Follow @AltimmuneInc on X

Investor Contact:

Luis Sanay, CFA

Vice President, Investor Relations

ir@altimmune.com

Media Contact:

Real Chemistry

altimmune@realchemistry.com